BK-5Cl-NM-AMT, or βk-5Cl-NM-αMT, also known as β-keto-5-chloro-N-methyl-αMT or α,N-dimethyl-5-chloro-β-ketotryptamine, is a monoamine releasing agent of the tryptamine, α-alkyltryptamine, and β-ketotryptamine families.^[1]

It is known to induce the release of serotonin and dopamine, with respective EC₅₀Tooltip half-maximal effective concentration values of 200 nM and 865 nM in rat brain synaptosomes, whereas norepinephrine release was not reported.^[1] In contrast to many other tryptamines, the drug is inactive as an agonist of serotonin receptors including the 5-HT₁, 5-HT₂, and 5-HT₃ receptors.^[1] In addition, unlike other α-alkyltryptamines like α-methyltryptamine (αMT), it is inactive as a monoamine oxidase inhibitor (MAOI).^[1]

BK-5Cl-NM-AMT was first described in the literature by 2023.^[1] It was patented by Matthew Baggott and Tactogen as a potential novel entactogen.^[1] BK-5Cl-NM-AMT is the 5-chloro derivative of BK-NM-AMT.^[1][2][3][4] Other analogues of the drug include BK-5F-NM-AMT and BK-5Br-NM-AMT.^[1]

• 5-Chloro-AMT

• β-Oxo-5-chloro-α-methyl-NMT (BK-5Cl-NM-AMT) - Isomer Design